Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, above 18 years of age
Diagnosis of essential hypertension
Newly diagnosed,
Previously untreated, or Currently untreated (not on regular antihypertensive treatment during the previous at least 1-month period)
Written informed consent
You may not be if
Known or suspected secondary hypertension
eGFR lower than 30 mL/min
Use of any other hypertension treatments during the enrollment and need for using the related treatments during the study phase
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. (i.e. valsartan, amlodipine, hydrochlorothiazide)
History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.Pregnant or nursing (lactating) women
